Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13625657 | 0.81 | ADRA1A (0.33) | — | |
| SCHEMBL18944207 | 0.80 | — | — | |
| SCHEMBL6900524 | 0.78 | CES2 (0.32) | CES2ALOX15CYP1B1ALDH1A1 | |
| SCHEMBL23408253 | 0.76 | FNTA (0.33) | CES2ALOX15CYP1B1ALDH1A1 | |
| SCHEMBL16302442 | 0.75 | CES2 (0.30) | CES2ALOX15CYP1B1ALDH1A1 | |
| SCHEMBL11172722 | 0.75 | CES2 (0.30) | CES2ALOX15CYP1B1ALDH1A1 | |
| SCHEMBL10056227 | 0.74 | — | — | |
| SCHEMBL13625397 | 0.73 | MEN1 (0.36) | ALDH1A1 | |
| SCHEMBL19647749 | 0.73 | CES2 (0.32) | CES2 | |
| SCHEMBL10084343 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767854-B2 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| EP-2014285-B1 | NPYY5 antagonists | SHIONOGI & CO (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| CN-101203483-A | N-substituted phenylacetamide derivatives and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-06-18 | — | — | CN | disclosed |
| EP-1884510-A1 | N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | HRH4, HRH2, CNR2 | SPHK1 3623/4885CES2 3851/4885ALOX15 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.